$ACMR

Wang David H sold $748K of ACMR

Wang David H (See Remarks) sold 8,581 shares of ACM Research, Inc. (ACMR) at $87.13 ($0.75M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wang David H
Published Jun 5, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ACMR
Neutral
medium confidence
Mentioned
$ACMR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACMRNeutralLow
01

Why it matters

The transaction is disclosed as an open-market sale executed under a pre-arranged Rule 10b5-1 plan, which generally lowers the information content about near-term company prospects.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 structure makes this more of a routine disclosure than a catalyst.

03

What to watch

The filing does not indicate whether additional insider buys/sales occurred around the same window, nor does it reveal the insider’s cost basis or tax-driven rationale.

Relevance 7/10Novelty 6/10Timing: Filed after-hours/late day (2026-06-05 20:30 UTC) for a 2026-06-04 sale.

Background

This is an SEC Form 4 insider transaction (officer/director/10% owner) reported for ACM Research, Inc.

Company-level read

Ticker impact

$ACMRNeutralMedium confidence
Context

ACMR disclosed an officer/director/10% owner open-market sale of 8,581 shares at $87.13 via a 10b5-1 plan.

Expected impact

Likely limited immediate impact; any effect is more sentiment/flow-related than fundamental.

Evidence & confidence

The filing is a routine Form 4 transaction and explicitly states a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider activity.

None.

None.

Counterpoint

A 10b5-1 sale can be purely mechanical (liquidity/tax planning) and should not be treated as a bearish signal.

Key entities

  • ACM Research, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Wang David H

    Officer, director, and 10% owner who sold 8,581 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACMRMed

AI Sovereignty Becomes a New National Security Battleground: Morgan Stanley Names SpaceX and 4 Other Beneficiary Stocks, with Upside Potential Topping 100% — BigGo Finance

Morgan Stanley identifies SpaceX, ACM Research, Amkor Technology, Alibaba, and KLA as key beneficiaries of the AI sovereignty trend. The bank assigns price targets with upside potential ranging from 21% to 105%, highlighting the strategic importance of AI infrastructure for national security and economic competitiveness.

$ACMRMed

ACM Research (NASDAQ: ACMR) unit’s orders surge past 100% with 42–48% margin outlook

ACM Research (Shanghai) reported a 105% year-over-year increase in new orders for the first half of 2026, with growth across electroplating, cleaning, and advanced packaging equipment. The company expects gross margins to remain between 42% and 48%. Significant orders include panel-level electroplating systems for delivery in 2026 and 2027. ACM Shanghai also highlighted rapid growth in mature-node semiconductor manufacturing and AI-related equipment demand.

$ACMRMedAI 9/10

ACM Research (ACMR) Q2 2026 Earnings Call Transcript

ACM Research (ACMR) reported Q2 2026 revenue of $292.9M, up 36% year over year, with non-GAAP diluted EPS of $0.61. Non-GAAP gross margin was 46.0%. The company raised 2026 revenue guidance to $1.125B-$1.175B and said first-half orders rose 105%. Net cash was $1.0B.